TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00853814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to sedentary behaviors
Description: Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to sedentary behaviors
Description: Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to sedentary behaviors
Description: Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to sedentary behaviors
Description: Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
Study: NCT03883633

Intervention type: BEHAVIORAL
Intervention: ReCODE Protocol
Description: Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
Study: NCT02683096

Intervention type: OTHER
Intervention: Observation
Description: Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.

Intervention type: OTHER
Intervention: Observation
Description: Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
Study: NCT00493922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test
Description: Introduction of rapid diagnostic test for malaria

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microscopy
Description: Microscopy for diagnosis of malaria

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical diagnosis for malaria
Description: The use of Clinical diagnosis for the diagnosis of malaria
Study: NCT02266797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
Study: NCT00529308

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (active)
Description: Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (sham)
Description: Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
Study: NCT04110340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician.

Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician.

Intervention type: DRUG
Group type: OTHER
Intervention: Streptomycin
Description: Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician.

Intervention type: DRUG
Group type: OTHER
Intervention: Gentamicin
Description: Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days.
Study: NCT03039530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: 9 weekly 2-hour group CBT sessions delivered by 2 trained Public Health Nurses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postnatal Care As Usual
Description: Postnatal care as usual will involve treatment from their family physician and midwife or obstetrician, and voluntary participation in programs offered by Niagara Region Public Health and in the community.
Study: NCT05233748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Resonance (SR)
Description: The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
Study: NCT01435083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: 120 µg, oral lyophilisate, sublingual use
Study: NCT01722968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 iv weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 iv weekly
Study: NCT03345238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling
Description: Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling
Description: Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling
Description: Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
Study: NCT02612311

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202: Oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202: Oral daily dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil: Oral dose
Study: NCT01409538

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Instructions
Description: There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control.
Study: NCT04492254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
Study: NCT03492281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vibegron
Description: single daily oral dose of vibegron 75 mg for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vibegron placebo
Description: placebo to match vibegron (experimental drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vibegron placebo
Description: placebo to match vibegron (experimental drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate ER
Description: single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolterodine placebo
Description: placebo to match tolterodine (active comparator)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine placebo
Description: placebo to match tolterodine (active comparator)
Study: NCT04586816

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1% red maple leaf extract in cream base
Description: 1% red maple leaf extract is combined in a cream base

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5% red maple leaf extract
Description: 5% red maple leaf extract is combined in a cream base

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: vehicle cream base only
Study: NCT02528110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 radical gastrectomy
Description: radical gastrectomy with D2 lymphadenectomy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: D2 radical gastrectomy
Description: radical gastrectomy with D2 lymphadenectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOX postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SOX postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XELOX postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: XELOX postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
Study: NCT03546491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preventive Gel
Description: 0.4% Stannous Fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Control
Description: 0.243% Sodium Fluoride
Study: NCT02802514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50mg
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50mg
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50mg
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50mg
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
Study: NCT03442686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compass Course
Description: An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
Study: NCT01528982

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Subjects receive mindfulness training
Study: NCT02802514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide matching placebo
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide matching placebo
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide matching placebo
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide matching placebo
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 10microgram
Description: It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
Study: NCT01528982

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognition
Description: Subject receive cognitive training
Study: NCT02862457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat 25 mg
Description: Oral administration
Study: NCT02802514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 10microgram
Description: It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 10microgram
Description: It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 10microgram
Description: It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide placebo (saline)
Description: It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide placebo (saline)
Description: It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide placebo (saline)
Description: It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide placebo (saline)
Description: It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
Study: NCT00903708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2275796
Description: 100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
Study: NCT04254523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) of bupicavaine
Description: Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (CEI) of bupivacaine
Description: A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (CEI) of morphine
Description: A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (CEI) of morphine
Description: A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
Study: NCT03392597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brothers as Allies
Description: Strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Programming-as-Usual
Description: Usual afterschool programming.
Study: NCT01745328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LVX-AMX
Description: Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
Study: NCT02862457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg
Description: Oral administration
Study: NCT01745328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCM
Description: Subject is treated with TCM for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LVX-AMX
Description: treatment with placebo from 2 to 4 weeks.
Study: NCT03483285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: airtraq videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: airtraq videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz
Description: storz videolaryngoscope
Study: NCT02862457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m^2
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Area Under the Curve (AUC) 5
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m^2
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6
Description: IV infusion